La vendita allo scoperto per Badlands Resources Inc dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Badlands Resources Inc. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Badlands Resources Inc (OTC:MNRLD) Azioni, Report sulle vendite allo scoperto

Badlands Resources Inc

Truist Securities analyst Michael Ciarmoli maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Hold and raises the price target from $270 to $304.

News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Curtiss-Wright, Raises Price Target to $304

On Friday, Gene Munster shared his insights on the ongoing AI market dynamics after key Nvidia supplier Taiwan Semiconductor Manufacturing Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) reported <a href="https://www.benzinga.com/news/earnings/24/10/41373163/nvidia-supplier-tsmc-reports-q3-revenue-earnings-beat-amid-rising-demand-for-ai-chips">impressive third-quarter performance</a>.
What Happened: Munster took to X and emphasized the importance of focusing on the broader AI landscape rather than short-term fluctuations. He pointed out that just two days prior, concerns arose among investors regarding a potential slowdown in the AI sector. This was sparked by ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) reducing its 2025 revenue forecast by approximately 18%. The prevailing theory suggested that a decline in demand for AI chip-making machines could indicate a slowdown in AI chip demand.
See Also: <a href="https://www.benzinga.com/news/24/09/40974511/iphone-15-pro-models-and-iphone-13-discontinued-by-apple-heres-why?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">iPhone 15 Pro Models and iPhone 13 Discontinued By Apple: Here&#8217;s Why</a>
However that was not the case. Munster highlighted that TSMC saw a 10% surge in its stock price after announcing a 6% increase in December revenue projections. TSMC also reported that its demand for CoWoS, a key AI technology, is outpacing its supply capabilities, despite efforts to double capacity annually. 
Munster stated, &#8220;I still believe we&#8217;re in front of a 2-4 year bull market driven by AI.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Today&#39;s another case study on why it&#39;s important to stay focused on the big AI picture versus the day-to-day noise. Two days ago, investors were concerned that the AI trade was starting to slow, based on <a href="https://twitter.com/search?q=%24ASML&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ASML</a> guiding 2025 revenue down by about 18%. The theory was that if the…
&mdash; Gene Munster (@munster_gene) <a href="https://twitter.com/munster_gene/status/1847010578017190048?ref_src=twsrc%5Etfw">October 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Munster&#8217;s comments come in the wake of TSMC&#8217;s impressive third-quarter results, which exceeded expectations due to robust demand for AI chips. TSMC&#8217;s revenue for the quarter reached NT$759.69 billion ($23.50 billion), marking a 39% year-over-year increase. This growth underscores the strong demand for advanced processor node technologies used in AI applications.
Additionally, Munster had previously addressed the market&#8217;s reaction to ASML&#8217;s guidance cut, describing it as an overreaction. As reported by <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41351475/after-asml-rocks-ai-hardware-names-gene-munster-explains-why-its-overreaction-ai-tr">Benzinga</a>, he noted that only a small portion of ASML&#8217;s revenue is directly tied to AI demand. Munster&#8217;s perspective suggests that the AI trade remains on track, with TSMC&#8217;s performance further supporting this outlook.
Price Action: As per<a href="https://pro.benzinga.com"> Benzinga Pro,</a> t the time of writing during the pre-market hours on Friday, Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up by 0.70% while major semiconductor ETFs were also trading slightly upwards. iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) was up by 1% while Direxion Daily Semiconductor Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NYSE">SOXL</a>) was trading 3.20% higher. SP Funds S&amp;P World ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPWO#NYSE">SPWO</a>) which allows investments into TSM, was up by 1.54%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41356479/apple-spark-hope-for-americas-semiconductor-comeback-key-supplier-tsmc-reportedly-begins-producing-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Spark Hope For America&#8217;s Semiconductor Comeback: Key Supplier TSMC Reportedly Begins Producing Chip</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Tech

General

ASML

SOXL

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

SPWO

Gene Munster Predicts 'Bull Market Driven By AI' Amid TSMC's Stellar Performance

Truist Securities analyst Michael Ciarmoli maintains Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) with a Hold and lowers the price target from $22 to $20.

ATRO

Truist Securities Maintains Hold on Astronics, Lowers Price Target to $20

Earnings

American Express CEO Says U.S. Consumer Is Stable But Spending Is Lower Than Post-Pandemic Levels; CFO Says Impact Of Fed Rate Cuts On Our Net Interest Income Is Actually Quite Small; CFO Says The Fed Rate Cut Is Too Small And Too Early To See Any Impact In Terms Of Spend Patterns

Citigroup analyst Andrew Schmidt downgrades Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) from Buy to Neutral and lowers the price target from $118 to $110.

Downgrades

EEFT

Citigroup Downgrades Euronet Worldwide to Neutral, Lowers Price Target to $110

RBC Capital analyst Shagun Singh maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and raises the price target from $525 to $555.

ISRG

RBC Capital Maintains Outperform on Intuitive Surgical, Raises Price Target to $555

Truist Securities analyst Michael Ciarmoli maintains AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) with a Buy and lowers the price target from $10 to $8.

ASLE

Truist Securities Maintains Buy on AerSale, Lowers Price Target to $8

P&G CFO Says Co Saw Stock-Up Situation As A Quick Run Up Due To The Port Strike Which Didn't Really Have A Material Impact On This Quarter; The Stock-Up Situation Due To Port Strikes Was Very Short-Lived

Citigroup analyst Scott Gruber downgrades Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) from Buy to Neutral and lowers the price target from $25 to $19.

LBRT

Citigroup Downgrades Liberty Energy to Neutral, Lowers Price Target to $19

American Express CFO Says Impact Of Fed Rate Cuts On Our Net Interest Income Is Actually Quite Small

Ladenburg Thalmann analyst Glenn Mattson initiates coverage on Neonode (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) with a Buy rating and announces Price Target of $16.5.

Initiation

NEON

Ladenburg Thalmann Initiates Coverage On Neonode with Buy Rating, Announces Price Target of $16.5

On Thursday,&nbsp;Aura Biosciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41390774/multiple-clinical-complete-responses-demonstrated-following-single-low-dose-administration-of-bel-" rel="noreferrer noopener">bladder cancer (NMIBC)</a>.
To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility of local administration of bel-sar alone (n=5) and bel-sar with light activation (n=8).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40837403/aura-biosciences-touts-promising-data-from-eye-cancer-candidate" rel="noreferrer noopener">Aura Biosciences Touts Promising Data From Eye Cancer Candidate</a>.
The secondary endpoints are to evaluate biological activity and immune-mediated changes in the tumor microenvironment (TME).
In patients receiving bel-sar with light activation (n=8), 4 out of 5 patients with low-grade disease demonstrated a clinically complete response with no tumor cells remaining on histopathological evaluation.
Two out of 3 patients with high-grade disease demonstrated visual tumor shrinkage observed on cystoscopy.
The data in these eight patients receiving bel-sar with light activation showed clinical activity detectable as soon as seven days after a single low dose of bel-sar with light activation.
&#8220;A potentially differentiating aspect of this novel treatment is the rapid tumor response accompanied by an immune-oncology effect such as a marked CD8+ T-cell infiltration observed in just a matter of days with a single low dose. We believe this could have the potential to translate into a durable response. In parallel with expanding the ongoing Phase 1 trial, we are preparing for a Phase 2 trial to further evaluate bel-sar&#8217;s clinical activity and durability of response,&#8221; said Sabine Brookman-May, Senior Vice President, Therapeutic Area Head Urologic Oncology of Aura Biosciences.
In the safety analysis as of Sept. 9, data cut-off date (n=12), bel-sar was well-tolerated, with less than 10% of patients reporting Grade 1 and no Grade 2 or higher drug-related adverse events reported.
No serious adverse events have been reported.
Price Action: AURA stock traded 18.85% higher at $12.23 during after-hours trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" target="_blank" rel="noreferrer noopener">Pharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

AURA

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

<ul>
<li>NVDA</li>
<li>NFLX</li>
<li>TSLA</li>
<li>AAPL</li>
<li>WAY</li>
<li>QQQ</li>
<li>MADE</li>
<li>AI</li>
<li>TSM</li>
<li>GOLD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

MADE

NFLX

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of October 18, 2024 (Via Swaggy Stocks)

Joe Rogan recently discussed how people are starting to think differently about capitalism, money and yes, one of his favorite topics – <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a>. In a <a href="https://www.youtube.com/watch?v=ws2ZsG3NNQc">conversation</a> with musician Jelly Roll, Rogan talked about how things are changing in both the entertainment world and the way people feel about capitalism. He said both areas have seen a lot of changes recently.
Don't Miss:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> 7-9% target yield with monthly dividends would you invest in it?</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
&#8220;Everybody&#8217;s worried about like this collapse of society because people, they give up on
capitalism. They tune in and drop out,&#8221; he started before saying, &#8220;I don&#8217;t think we should be worried about that. I don&#8217;t think that&#8217;s real.&#8221;&nbsp;
He believes that while some people might want to &#8220;drop out&#8221; of the system, it won't affect most people. He thinks those people are just the type who would probably reject the system no matter what.
Trending: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
Rogan added that some people will always want to drop out and avoid responsibility. If given an excuse, they will take it, but that's just their personality. He believes this type of person doesn't represent most people and that most people could benefit from the system, especially if they don&#8217;t have major mental health issues.
Although Rogan and Roll talked a lot about psychedelics in this episode, what&#8217;s more interesting is what Rogan discussed in a different episode with Michael Malice. In it, they talked about how psychedelics, like <a href="https://www.benzinga.com/markets/cannabis/24/09/40858292/magic-mushrooms-boosted-humanitys-evolutionary-success-new-study-says-did-psilocybin-make-early-">magic mushrooms</a>, could change the corporate world.&nbsp;
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Yes, Rogan said that if these drugs became legal and business leaders started using them, <a href="https://www.benzinga.com/personal-finance/24/08/40133472/joe-rogan-tells-ceos-life-is-short-youre-wasting-all-your-time-trying-to-squeeze-as-much-money-a">they might start to care more about people</a> and less about making as much money as possible. He said this is a &#8220;psychedelic capitalist perspective,&#8221; in which maximizing profits is equated with doing the right thing and not hurting anyone.
On a similar note, Rogan laughed and added that this might even make it &#8220;much harder to get a good burger&#8221; since fast-food workers might quit their jobs after taking psychedelics and seeing things differently.
Trending: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
In 2017, he compared this way of thinking to former President Donald Trump, saying Trump is like someone who believes &#8220;greed is good.&#8221; Rogan warned that this thinking is &#8220;a dangerous ideology&#8221; for society, saying, "I mean, our president is essentially the greed-is-good guy. I mean, that is who he is that's what he's done. He's pursued wealth at all cost."
Rogan&#8217;s ideas aren't without controversy. Even though he often talks <a href="https://www.benzinga.com/personal-finance/24/09/40909092/joe-rogan-says-education-addiction-recovery-and-homelessness-should-be-funded-more-its-a-good-id">against corporate greed</a>, he is friends with some of the world&#8217;s richest and most powerful people. He called <a href="https://www.benzinga.com/news/24/05/38978082/joe-rogan-says-elon-musk-is-his-favorite-billionaire-i-will-buy-teslas-as-long-as-they-sell-them-jus">Elon Musk his &#8220;favorite billionaire&#8221;</a> and said he&#8217;d keep buying Tesla cars to support him. Some have referred to Rogan as hypocritical because of this, particularly considering that his podcast is among the most popular.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>

Startups

'I Don't Think We Should Be Worried About That,' Says Joe Rogan About People Giving Up On Capitalism – 'I Don't Think That's Real'

Lake Street analyst Jacob Stephan downgrades Zuora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZUO#NYSE">ZUO</a>) from Buy to Hold and announces $10 price target.

Lake Street Downgrades Zuora to Hold, Announces $10 Price Target

Morgan Stanley analyst Bob Huang maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $300 to $310.

Morgan Stanley Maintains Overweight on Progressive, Raises Price Target to $310

Lake Street analyst Ben Klieve downgrades MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) from Buy to Hold and announces $75 price target.

MGPI

Lake Street Downgrades MGP Ingredients to Hold, Announces $75 Price Target

WIIM

Procter & Gamble shares are trading lower following a Q1 revenue miss.

Morgan Stanley analyst Michael Cyprys maintains T. Rowe Price Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Equal-Weight and raises the price target from $125 to $127.

TROW

Morgan Stanley Maintains Equal-Weight on T. Rowe Price Gr, Raises Price Target to $127

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 90 points on Friday.
Shares of CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) fell sharply in today's pre-market trading after the company cut its <a href="https://www.benzinga.com/quote/CVS">third-quarter outlook.</a>
CVS Health appointed longtime executive David Joyner as its new president and CEO, replacing Karen Lynch amid the company's ongoing financial struggles. The company warned that its upcoming third-quarter earnings, set for release on November 6, will miss Wall Street projections.
CVS Health shares dipped 11.6% to $56.29 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>MGP Ingredients, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) shares dipped 16.6% to $68.06 after the company issued soft preliminary guidance and lowered its 2024 financial outlook.</li>
<li>Coherent Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NASDAQ">COHR</a>) shares fell 4.6% to $97.39 in pre-market trading.</li>
<li>Zeta Global Holdings Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) shares fell 4.5% to $28.66 in pre-market trading. Zeta is expected to release its third quarter 2024 financial results after the closing bell on Monday, Nov. 11.</li>
<li>Jin Medical International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 4.3% to $2.03 in pre-market trading after declining around 5% on Thursday.</li>
<li>GrafTech International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NASDAQ">EAF</a>) shares fell 4.1% to $1.62 in pre-market trading.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) shares fell 3.8% to $2.55 in pre-market trading. HC Wainwright &amp; Co. analyst Amit Dayal reiterated Gevo with a Buy and maintained a $14 price target.</li>
<li>American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) shares fell 3.6% to $275.50 in pre-market trading following third-quarter results.</li>
<li>Fresh Del Monte Produce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) shares fell 3.5% to $29.00 in pre-market trading. Fresh Del Monte Produce will issue a press release on its third quarter financial results prior to market opening on Thursday, Oct. 31.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41390636/top-2-real-estate-stocks-that-may-fall-off-a-cliff-in-q4">Top 2 Real Estate Stocks That May Fall Off A Cliff In Q4</a></li>
</ul>

Comments

Badlands Resources Inc

Vendite allo scoperto

Badlands Resources Inc (OTC:MNRLD) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO